Table 1.

Risk of cervical cancer associated with SDC-1 polymorphisms, by histologic type and study

GenotypeControl
Squamous cell carcinoma
Adenocarcinoma
n (%)n (%)OR (95% CI)OR (95% CI)*n (%)OR (95% CI)OR (95% CI)*
Exon 3 (rs2230924) polymorphism
    Eastern U.S. Study
        GG123 (53.0)60 (49.6)1.01.062 (49.6)1.01.0
        AG/AA109 (47.0)61 (50.4)1.1 (0.74-1.8)1.2 (0.77-1.9)63 (50.4)1.1 (0.74-1.8)1.1 (0.74-1.8)
        AG95 (41.0)54 (44.6)1.2 (0.74-1.8)1.2 (0.77-1.9)53 (42.4)1.1 (0.70-1.7)1.1 (0.70-1.7)
        AA14 (6.0)7 (5.8)1.0 (0.39-2.7)1.2 (0.44-3.1)10 (8.0)1.4 (0.60-3.4)1.4 (0.60-3.4)
Pro-27 (rs11544860) polymorphism
    Eastern U.S. Study
        CC204 (89.5)105 (87.5)1.01.0102 (82.3)1.01.0
        CT/TT24 (10.5)15 (12.5)1.2 (0.61-2.4)1.2 (0.56-2.4)22 (17.7)1.8 (1.0-3.4)1.8 (0.95-3.4)
        CT23 (10.1)15 (12.5)1.3 (0.63-2.5)1.2 (0.58-2.5)22 (17.7)1.9 (1.0-3.6)1.9 (1.0-3.5)
        TT1 (0.4)0 (0.0)0 (0.0)
    Seattle Area Study
        CC98 (86.0)75 (85.2)1.01.0110 (82.7)1.01.0
        CT/TT16 (14.0)13 (14.8)1.1 (0.48-2.3)1.3 (0.58-2.9)23 (17.3)1.3 (0.64-2.6)1.2 (0.60-2.5)
        CT15 (13.2)13 (14.8)1.1 (0.51-2.5)1.4 (0.61-3.1)22 (16.5)1.3 (0.64-2.7)1.3 (0.61-2.7)
        TT1 (0.9)0 (0.0)1 (0.8)0.9 (0.06-14)0.6 (0.03-9.3)
    Pooled analyses
        CC302 (88.3)180 (86.5)1.01.0212 (82.5)1.01.0
        CT/TT40 (11.7)28 (13.5)1.2 (0.70-2.0)1.2 (0.70-2.1)45 (17.5)1.6 (1.0-2.5)1.6 (0.99-2.6)
        CT38 (11.1)28 (13.5)1.2 (0.73-2.1)1.3 (0.74-2.2)44 (17.1)1.6 (1.0-2.6)1.7 (1.0-2.7)
        TT2 (0.6)0 (0.0)1 (0.4)0.7 (0.06-7.9)0.5 (0.04-5.6)
  • * Adjusted for age, race, and study site where appropriate.